Treatment effects of CAP combined with verapamil in chemotherapy of patients with advanced lung adenocarcinoma
- VernacularTitle:CAP方案联合维拉帕米治疗晚期肺腺癌疗效分析
- Author:
Yide HU
;
Qichao XIE
;
Hongmei WANG
;
- Publication Type:Journal Article
- Keywords:
verapamil;
multidrug resistance;
lung adenocarcinoma;
chemotherapy
- From:Journal of Third Military Medical University
2003;0(16):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic efficacy and side effects of cyclopnosphamide, adriamycin, cisplatin (CAP) or CAP combined with verapamil(VPL) in chemotherapy of patients with advanced lung adenocarcinoma. Methods A total of 56 patients(male: 27, female: 29, average age: 48 years old, age range: 32-78 years old) with stage Ⅲb/Ⅳ lung adenocarcinoma confirmed pathologically from April 1998 to December 2001 were divided into two groups: group A(30 patients), treated with cyclophosphamide (CTX, 600 mg?m -2 ?d -1 ) on days 1 and 8, adriamycin (ADM, 40 mg/m 2) on day 1, and cisplatin (CDDP, 30 mg?m -2 ?d -1 ) on days 1, 2 and 3 and group B(26 patients), treated with the same dose of CTX, ADM and CDDP and an additional oral VPL treatment (60 mg t.i.d . on days 1-7). Each of the 3 cycles was repeated every 21 days. Results The patients in group A had a lower response rate (26.7% vs 38.5%, P
